300+ investors in your industry, stage, and region Get
Any industry
Artificial Intelligence
Google
EdTech
Clean Energy
Retail
Enterprise Software
Local
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Renewable Energy
Organic Food
Email
Fitness
CleanTech
Energy
Health Care
Machine Learning
Agriculture (AgTech)
Marketplace
Gaming
Social Network
Facebook
Blockchain
B2B
Big Data
Video Games
Education
Wellness
Medical Device
Mobile
Legal
Sports
Construction
Automotive
eSports
Hospitality
Biotechnology
Consumer
Software
Crowdfunding
Web3
Medical
Theatre
Recruiting
Venture Capital
Social
Infrastructure
Fashion
Beauty
LGBT
Celebrity
Cannabis
Climate
Mobile Apps
Life Science
Publishing
Food and Beverage
Wine and Spirits
Real Estate
Sporting Goods
Art
Music
Finance
Digital Media
FinTech
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Mobile Advertising
Internet
Android
Impact
Biotech
Proptech
Sustainability
Hardware
Transportation
Enterprise
Community
Media (Entertainment)
Any country
South Korea
Africa
Oceania
Brazil
Saudi Arabia
Singapore
LATAM
Greece
Gibraltar
Norway
Liberia
Mexico
Taiwan
Sweden
Zambia
Puerto Rico
Tunisia
Nigeria
Isle of Man
Pakistan
Russian Federation
Romania
Togo
Tajikistan
Zimbabwe
Cameroon
Oman
Australia
Colombia
India
New Zealand
China
Sri Lanka
Vietnam
Armenia
Costa Rica
Chile
Switzerland
Czech Republic
Kenya
Cayman Islands
Kuwait
Kazakhstan
Jamaica
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uganda
Turkey
Uzbekistan
Venezuela
Guatemala
Germany
Seychelles
Japan
South Africa
Egypt
France
Georgia
Denmark
Croatia
Hong Kong
Ghana
Iraq
Mali
Morocco
Myanmar
Latvia
Malaysia
Portugal
Philippines
Poland
Rwanda
Sierra Leone
Senegal
Thailand
El Salvador
Uruguay
Tanzania
United Kingdom
United States
Canada
Ireland
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Cyprus
Qatar
United Arab Emirates
Spain
Angola
Europe
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Bahrain
Bahamas
Estonia
Faroe Islands
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Iceland
Cambodia
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology VC Funds & Investors in Europe (June 2026)

The most active venture capital funds investing in Europe Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Europe Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Bpifrance
VC Fund
79 France, United States, Switzerland Seed, Series A Software, Information Technology, Health Care $713k–$35M
SOSV
VC Fund
77 United States, India, United Kingdom Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software
Sofinnova Partners
VC Fund
71 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6M–$120M
UK Innovation & Science Seed Fund
VC Fund
57 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Medical $393k–$14M
HTGF (High-Tech Gruenderfonds)
VC Fund
55 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology $994k–$40M
Novo Holdings
VC Fund
52 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9M–$130M
Parkwalk Advisors
VC Fund
44 United Kingdom, United States, Philippines Seed, Series A, Series B Biotechnology, Health Care, Software $982k–$46M
Scottish Enterprise
VC Fund
43 United Kingdom, United States, Japan Grant, Seed Biotechnology, Software, Health Care $104k–$4.8M
Oxford Science Enterprises
VC Fund
41 United Kingdom, United States, Finland Seed, Series A, Series B Health Care, Biotechnology, Software $1.3M–$168M
Kurma Partners
VC Fund
35 France, Switzerland, Spain Series A, Seed, Series B Health Care, Biotechnology, Medical $2.3M–$95M
Seventure Partners
VC Fund
35 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $3.1M–$65M
Oxford Technology Management
VC Fund
34 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Software $33k–$7.9M
Boehringer Ingelheim Venture Fund
VC Fund
31 United States, Germany, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.3M–$50M
Catapult Ventures
VC Fund
29 United Kingdom, United States, Israel Seed, Series A Health Care, Biotechnology, Medical $150k–$26M
Enterprise Ireland
VC Fund
29 Ireland, United States, United Kingdom Seed, Series A Software, Information Technology, Health Care $494k–$12M
Scottish Investment Bank
VC Fund
28 United Kingdom, United States, France Seed, Series A Software, Biotechnology, Health Care $327k–$7M
Mercia Fund Managers
VC Fund
27 United Kingdom, United States, Hungary Seed, Series A Software, Health Care, Biotechnology $196k–$14M
GO CAPITAL
VC Fund
27 France, Canada, Israel Seed, Series A Biotechnology, Software, Health Care $516k–$13M
M Ventures
VC Fund
25 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
Forbion Capital Partners
VC Fund
25 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $15M–$176M
Epidarex Capital
VC Fund
25 United Kingdom, United States, Germany Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $531k–$55M
Centre for the Development of Industrial Technology (CDTI)
VC Fund
25 Spain, United States, France Grant, Seed Biotechnology, Health Care, Software $155k–$19M
Development Bank of Wales
VC Fund
24 United Kingdom, Australia, United States Seed, Debt Financing Software, Health Care, Biotechnology $18k–$3.7M
Elaia
VC Fund
23 France, United States, Spain Seed, Series A, Series B Software, Artificial Intelligence, Information Technology $1.1M–$50M
Karista
VC Fund
23 France, United States, Finland Seed, Series A, Series B Software, Biotechnology, Health Care $713k–$43M
SFC Capital
VC Fund
23 United Kingdom, United States, Canada Pre-Seed, Seed Software, Artificial Intelligence, Information Technology $162k–$2.2M
Archangels
VC Fund
22 United Kingdom, United States Seed, Series A Software, Biotechnology, Health Care $1.3M–$8.3M
IP Group
VC Fund
22 United Kingdom, United States, Australia Seed, Series A Health Care, Biotechnology, Therapeutics $393k–$23M
HealthCap
VC Fund
21 United States, Sweden, France Series B, Series A Biotechnology, Health Care, Medical $5.7M–$88M
BioInnovation Institute
VC Fund
21 Denmark, Germany, Switzerland Convertible Note, Pre-Seed, Debt Financing Biotechnology, Medical, Health Care $516k–$5.2M
Omnes Capital
VC Fund
21 France, Germany, United States Series A, Series B Software, Biotechnology, Health Care $3.5M–$44M
AlbionVC
VC Fund
21 United Kingdom, United States, France Series A, Seed Software, Information Technology, Health Care $2.2M–$20M
MIG Capital
VC Fund
21 Germany, France, Austria Series A, Series B Biotechnology, Health Care, Therapeutics $1.6M–$54M
Future Planet Capital
VC Fund
20 United Kingdom, United States, Spain Seed, Convertible Note Biotechnology, Health Care, Software $897k–$7.9M
Meusinvest (Noshaq)
VC Fund
20 Belgium, France, Germany Series A, Seed Biotechnology, Health Care, Medical $137k–$16M
O2h Ventures
VC Fund
20 United Kingdom, Hungary Seed, Series A Biotechnology, Health Care, Pharmaceutical $655k–$26M
Auriga Partners
VC Fund
20 France, United States, Switzerland Series B, Series A Biotechnology, Health Care, Medical $2.2M–$33M
Northstar Ventures
VC Fund
19 United Kingdom, United States, Indonesia Seed, Series A Software, Health Care, E-Commerce $39k–$9.7M
GM&C Life Sciences Fund
VC Fund
19 United Kingdom, Italy, Germany Seed, Series A Health Care, Biotechnology, Medical $65k–$4.1M
Deepbridge Capital
VC Fund
19 United Kingdom, Australia, Singapore Seed, Series A Health Care, Biotechnology, Medical $152k–$15M
AdBio partners
VC Fund
19 France, Spain, Belgium Seed, Series A Biotechnology, Health Care, Pharmaceutical $2.2M–$37M
Idinvest Partners
VC Fund
19 France, United States, Spain Series B, Series A Biotechnology, Health Care, Software $3.3M–$66M
Wren Capital
VC Fund
18 United Kingdom Seed, Series A Biotechnology, Health Care, Medical $1.1M–$32M
Ysios Capital
VC Fund
18 Spain, United States, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Medical $2.2M–$135M
Chalmers Ventures AB
VC Fund
18 Sweden Pre-Seed, Seed Software, Biotechnology, Health Care $5k–$2.7M
Newable Private Investing
VC Fund
18 United Kingdom, United States Seed, Series A Software, Health Care, Biotechnology
Octopus Ventures
VC Fund
18 United Kingdom, United States, Germany Series A, Seed, Series B Software, Health Care, Information Technology $1.9M–$48M
Cambridge Innovation Capital
VC Fund
18 United Kingdom, United States, Ireland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2M–$73M
Hoxton Ventures
VC Fund
18 United Kingdom, United States, Canada Seed, Series A Artificial Intelligence, Software, Health Care $1.8M–$29M
PMV
VC Fund
17 Belgium, United States, The Netherlands Series A, Seed Software, Biotechnology, Health Care $549k–$40M
Access all 50 VC funds in Europe Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 79 investments in Europe Biotechnology startups

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 1073
  • Round size: Seed $713k–$6.9M; Series A $2.6M–$35M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
  • Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
  • Latitude — Venture Orbital Systems provides a tailor-made service for NanoSat & CubeSat operators.
Show all investments...

SOSV
VC Fund · Princeton, New Jersey, United States · 77 investments in Europe Biotechnology startups, 75 in the past 12 months

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1482
  • Lead/follow: no public data

Portfolio highlights

  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 71 investments in Europe Biotechnology startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 309
  • Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: Likely still investing — raised $200M in 2023

Portfolio highlights

  • Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
  • l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
  • EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
Show all investments...

UK Innovation & Science Seed Fund
VC Fund · Harwell, Oxfordshire, United Kingdom · 57 investments in Europe Biotechnology startups

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 131
  • Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • HonuWorx — HonuWorx is a subsea robotics company founded with a mission to replace surface vessels with underwater deployment platforms.
  • NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
  • Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 55 investments in Europe Biotechnology startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 557
  • Round size: Seed $994k–$7.4M; Series A $3M–$40M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — raised $522M in 2022

Portfolio highlights

  • QphoX — QphoX builds quantum modem device, connecting quantum computers across a quantum network.
  • Zimory — Founded in 2007, Zimory provides carrier-grade cloud infrastructure management software that allows service providers, enterprises and cloud brokers to fully leverage the power and elasticity of cloud computing. Zimory’s intelligent Cloud Suite simplifies, automates and expedites the creation, launch and management of all types of cloudenvironments – whether public, private, virtual private or hybrid. Zimory software is also a key enabler of cloud marketplaces for enterprise services, applications and infrastructure. Headquartered in Berlin, Zimory has development centers in Erfurt, Germany and Minsk, Belarus, a subsidiary office in New York City and is expanding its expertise and presence globally.
  • BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 52 investments in Europe Biotechnology startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 335
  • Round size: Series A $9M–$120M; Series B $12M–$130M; Series C $30M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
  • PTC Therapeutics — Translating Science. Transforming Lives.
  • Freeline — A leading biotechnology company focused on innovative liver directed gene therapies for bleeding disorders and other debilitating, chronic diseases
Show all investments...

Parkwalk Advisors
VC Fund · London, England, United Kingdom · 44 investments in Europe Biotechnology startups

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Philippines

Investor stats

  • Total investments: 259
  • Round size: Seed $982k–$5M; Series A $1.6M–$13M; Series B $2M–$46M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
  • Bramble Energy — Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the batteryindustry has spent many years and £B’s to achieve.Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack.Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.
Show all investments...

Scottish Enterprise
VC Fund · Glasgow, Glasgow City, United Kingdom · 43 investments in Europe Biotechnology startups

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Grant, Seed
  • Geography: United Kingdom, United States, Japan

Investor stats

  • Total investments: 313
  • Round size: Seed $318k–$3.8M; Grant $104k–$4.8M
  • Lead/follow: 36% lead, 64% follow

Portfolio highlights

  • Gigged.AI — Fill skill gaps using our on-demand talent network. Get AI-powered, real-time visibility over your employee and agent capabilities to power internal mobility.
  • RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
  • Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Show all investments...

Oxford Science Enterprises
VC Fund · Oxford, Oxfordshire, United Kingdom · 41 investments in Europe Biotechnology startups

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Finland

Investor stats

  • Total investments: 166
  • Round size: Seed $1.3M–$12M; Series A $5M–$46M; Series B $8.5M–$168M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — raised $327M in 2022

Portfolio highlights

  • Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
  • Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
  • Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
Show all investments...

Kurma Partners
VC Fund · Paris, Ile-de-France, France · 35 investments in Europe Biotechnology startups

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: France, Switzerland, Spain

Investor stats

  • Total investments: 132
  • Round size: Seed $2.3M–$13M; Series A $3.8M–$95M; Series B $8.8M–$80M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
  • Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Seventure Partners
VC Fund · Paris, Ile-de-France, France · 35 investments in Europe Biotechnology startups

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 218
  • Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Sentryc — Protect your brand and your products from counterfeiters with Sentryc. We monitor over 120 marketplaces for you and remove potential counterfeits.
  • Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
  • Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Show all investments...

Oxford Technology Management
VC Fund · Oxford, Oxfordshire, United Kingdom · 34 investments in Europe Biotechnology startups

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 107
  • Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: May invest from a new fund soon — last raise in 2012

Portfolio highlights

  • OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
  • CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
  • Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 31 investments in Europe Biotechnology startups

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Switzerland

Investor stats

  • Total investments: 98
  • Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2018

Portfolio highlights

  • ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
  • Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
  • Centauri Therapeutics — At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.
Show all investments...

Catapult Ventures
VC Fund · Leicester, Leicester, United Kingdom · 29 investments in Europe Biotechnology startups

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Israel

Investor stats

  • Total investments: 104
  • Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Rinicare — Rinicare is Lancaster-based SME that offers innovative technology solutions for healthcare applications.
  • Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
  • Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
Show all investments...

Enterprise Ireland
VC Fund · Dublin, Dublin, Ireland · 29 investments in Europe Biotechnology startups

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Ireland, United States, United Kingdom

Investor stats

  • Total investments: 506
  • Round size: Seed $494k–$3.3M; Series A $2.2M–$12M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: May invest from a new fund soon — raised $1.1M in 2021

Portfolio highlights

  • Tirlan — Tirlan is an agricultural company that supplies agri-food and farm input materials to the framing sector.
  • Pulsate — Pulsate enables direct communication with customers based on their location, context, interests and behaviours. Pulsate allows you to design and push rich media content directly to customers devices. Deepen the relationship by establishing a customer dialogue. Allow users to reply to your campaigns, provide feedback and keep complaints outside ofsocial media. Maximize foot traffic by targeting street level or competitor locations. Combine with segmentation for optimal results. iBeacons:tm: enable you to understand indoor customer location and context with incredible accuracy. Easily manage deployment and configuration of iBeacons:tm: with the Pulsate cloud platform. Gain a deeper understanding of your mobile customers and a comprehensive view of each mobile campaign.
  • Lakeland Dairies — Lakeland Dairies, a major dairy processing co-operative, operates within a fifteen county catchment area across the northern half of the island of Ireland. The Group processes about one billion litres of quality milk annually into a range of value added dairy foodservice products and functional dairy food ingredients.
Show all investments...

Scottish Investment Bank
VC Fund · Glasgow, Glasgow City, United Kingdom · 28 investments in Europe Biotechnology startups

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 208
  • Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
  • Lead/follow: 11% lead, 89% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
  • IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
  • Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Show all investments...

Mercia Fund Managers
VC Fund · Henley In Arden, Warwickshire, United Kingdom · 27 investments in Europe Biotechnology startups

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Hungary

Investor stats

  • Total investments: 135
  • Round size: Seed $196k–$2M; Series A $2M–$14M
  • Lead/follow: 67% lead, 33% follow
  • Last fund: May invest from a new fund soon — last raise in 2013

Portfolio highlights

  • Sen — Sen's vision is to democratize space using video to inform, educate, inspire and benefit all humanity. Sen's mission is to stream real-time videos from space to billions of people, gathering news and information about Earth and space and making it universally accessible.
  • 4D Medicine
  • Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
Show all investments...

GO CAPITAL
VC Fund · Rennes, Bretagne, France · 27 investments in Europe Biotechnology startups

GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A
  • Geography: France, Canada, Israel

Investor stats

  • Total investments: 135
  • Round size: Seed $516k–$5.5M; Series A $2.1M–$13M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Episto — Episto helps you collect ultra-authentic insights from your targets, anywhere in the world, simply and instantly
  • AISPRID — AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.
  • NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 25 investments in Europe Biotechnology startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 170
  • Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
  • Biolinq — Introducing a revolutionary platform for metabolic health.
  • Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 25 investments in Europe Biotechnology startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 187
  • Round size: Series A $16M–$176M; Series B $15M–$155M; Series C $19M–$113M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
  • Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
  • Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Epidarex Capital
VC Fund · Bethesda, Maryland, United States · 25 investments in Europe Biotechnology startups

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 48
  • Round size: Seed $531k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$55M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
  • AdoRx Therapeutics — AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effectsof high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.
  • Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Show all investments...

Centre for the Development of Industrial Technology (CDTI)
VC Fund · Madrid, Madrid, Spain · 25 investments in Europe Biotechnology startups

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Grant, Seed
  • Geography: Spain, United States, France

Investor stats

  • Total investments: 186
  • Round size: Seed $562k–$5.9M; Grant $155k–$19M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • Xoople — Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface.
  • TetraxAI — TetraxAI helps renewable energy developers and investors automate due diligence and risk assessment - 100x faster, 10x cheaper, with full legal traceability.
  • Golden Owl
Show all investments...

Development Bank of Wales
VC Fund · Cardiff, Cardiff, United Kingdom · 24 investments in Europe Biotechnology startups

Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Debt Financing
  • Geography: United Kingdom, Australia, United States

Investor stats

  • Total investments: 221
  • Round size: Seed $327k–$3.7M; Debt Financing $18k–$3.7M
  • Lead/follow: 59% lead, 41% follow
  • Last fund: May invest from a new fund soon — raised $25M in 2018

Portfolio highlights

  • Tourhub — tourhub - We collect tours from hundreds of suppliers around the world and provide an easy way for you to search and find those that are of interest.
  • Antiverse — Designing biologics for 100 challenging targets
  • Hope Macy — Hope Macy is the decisioning and origination layer that modern consumer lenders build on.
Show all investments...

Elaia
VC Fund · Paris, Ile-de-France, France · 23 investments in Europe Biotechnology startups

Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 214
  • Round size: Seed $1.1M–$9.9M; Series A $2.2M–$26M; Series B $4.2M–$50M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Elevo — Elevo is a Paris-based performance management platform.
  • Vibe — Advertise your brand on CTV & OTT content with Vibe's self-serve ad platform to target hundreds of channels & networks and reach millions of households.
  • Traefik Labs — Cloud-native, GitOps-driven API runtime solutions for demanding DevOps and Platform Engineers with diverse use-cases, environments, and deployment models.
Show all investments...

Karista
VC Fund · Paris, Ile-de-France, France · 23 investments in Europe Biotechnology startups

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Finland

Investor stats

  • Total investments: 147
  • Round size: Seed $713k–$6.6M; Series A $1.2M–$18M; Series B $2.5M–$43M
  • Lead/follow: 16% lead, 84% follow

Portfolio highlights

  • CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
  • Physikron — Physikron is a developer of mass spectrometry technologies used to improve the performance of tandem spectrometry. Its technologies offer proteomic analysis and dramatically improves the number of peptides and proteins identified during an LC/MS/MS acquisition that enable researchers to research in an enhanced way.
  • Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Show all investments...

SFC Capital
VC Fund · London, England, United Kingdom · 23 investments in Europe Biotechnology startups

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Pre-Seed, Seed
  • Geography: United Kingdom, United States, Canada

Investor stats

  • Total investments: 378
  • Round size: Seed $164k–$2.2M; Pre-Seed $162k–$840k
  • Lead/follow: 39% lead, 61% follow
  • Last fund: May invest from a new fund soon — raised $1.9M in 2019

Portfolio highlights

  • Elaitra — Elaitra’s breast cancer platform includes a Generative LLM for voice-based patient engagement, and a unique AI reading tool that helps doctors read 3D X-Rays. Operating in USA & UK. FDA 510(k) and UK regulator approved.
  • Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
  • WeFindFlats — Live and work anywhere, without housing worries.
Show all investments...

Archangels
VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 22 investments in Europe Biotechnology startups

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 84
  • Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
  • Lead/follow: 54% lead, 46% follow

Portfolio highlights

  • BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
  • Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.
  • Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Show all investments...

IP Group
VC Fund · London, England, United Kingdom · 22 investments in Europe Biotechnology startups

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Therapeutics
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Australia

Investor stats

  • Total investments: 191
  • Round size: Seed $393k–$7.6M; Series A $2M–$23M
  • Lead/follow: 21% lead, 79% follow
  • Last fund: May invest from a new fund soon — raised $125M in 2014

Portfolio highlights

  • Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
  • Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
  • AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Show all investments...

HealthCap
VC Fund · Stockholm, Stockholms Lan, Sweden · 21 investments in Europe Biotechnology startups

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: United States, Sweden, France

Investor stats

  • Total investments: 126
  • Round size: Series A $5.7M–$55M; Series B $12M–$88M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — raised $209M in 2019

Portfolio highlights

  • Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
  • Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Show all investments...

BioInnovation Institute
VC Fund · Copenhagen, Hovedstaden, Denmark · 21 investments in Europe Biotechnology startups

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Convertible Note, Pre-Seed, Debt Financing
  • Geography: Denmark, Germany, Switzerland

Investor stats

  • Total investments: 73
  • Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
  • Lead/follow: 90% lead, 10% follow

Portfolio highlights

  • Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
  • Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
  • metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Omnes Capital
VC Fund · Paris, Ile-de-France, France · 21 investments in Europe Biotechnology startups

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Series B
  • Geography: France, Germany, United States

Investor stats

  • Total investments: 180
  • Round size: Series A $3.5M–$44M; Series B $4.4M–$43M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $403M in 2020

Portfolio highlights

  • SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
  • Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
  • Capsule Labs — We create frictionless web3 solutions for widespread adoption / Capsule Corp Labs
Show all investments...

AlbionVC
VC Fund · London, England, United Kingdom · 21 investments in Europe Biotechnology startups

AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Series A, Seed
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 164
  • Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • Runa — Businesses from every walk of life use rewards to acquire, retain and thank customers but the current process is broken. Sending rewards, incentives and non-cash payouts is manual, expensive, time-consuming and error-prone. WeGift changes this. Operating in more than 30 countries, in 22 languages, 20 currencies, with over 700 brand partners, andhundreds of clients, like Perkbox, Sodexo, New Look and Halfords among others, WeGift’s cloud-based, open API solutions allow businesses to transfer value to consumers, in real-time and globally. Established in 2016, WeGift is backed by leading entrepreneurs and investors.
  • Hussle — Gym membership with total flexibility. Gym passes to no contract gym memberships that you can use in thousands of gyms across the UK. Gym and swim wherever you want to. Stop and start whenever you like.
  • Clear Review — Enable conversations to drive meaningful relationships and ensure employees feel supported to reach their goals, so organisations can achieve what matters most.
Show all investments...

MIG Capital
VC Fund · München, Bayern, Germany · 21 investments in Europe Biotechnology startups

MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B
  • Geography: Germany, France, Austria

Investor stats

  • Total investments: 96
  • Round size: Series A $2.2M–$40M; Series B $1.6M–$54M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: May invest from a new fund soon — raised $70M in 2014

Portfolio highlights

  • NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
  • GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
  • Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
Show all investments...

Future Planet Capital
VC Fund · London, England, United Kingdom · 20 investments in Europe Biotechnology startups

Brilliant Ideas. Brilliant People. Brilliant Minds.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note
  • Geography: United Kingdom, United States, Spain

Investor stats

  • Total investments: 145
  • Round size: Seed $897k–$7.9M
  • Lead/follow: 8% lead, 92% follow
  • Last fund: Likely still investing — raised $23M in 2022

Portfolio highlights

  • Rovco — Rovco designs an autonomous underwater vehicle or AUV and remotely operated underwater vehicle or ROV technologies and support services that optimizes how people manage and inspect subsea assets. Its technology offers the process of 3D photogrammetry that involves using high-resolution photos of a static object or site area taken from multipleangles and processed to generate a 3D vector model from point cloud data, enabling oil, gas, and renewables industry clients to evaluate their subsea assets for damage, corrosion or determining levels of marine growth and benefit from inspection related cost savings.
  • Aloqia — Take control of your excess inventory with Aloqia. Resell, reuse, recycle, and prevent surplus while driving sustainability and supply chain resilience.
  • Captura — Captura is harnessing the power of the ocean to heal the climate through Direct Ocean Capture technology.
Show all investments...

Meusinvest (Noshaq)
VC Fund · Liège, Liege, Belgium · 20 investments in Europe Biotechnology startups

Noshaq offers financial services to help businesses develop.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed
  • Geography: Belgium, France, Germany

Investor stats

  • Total investments: 76
  • Round size: Seed $137k–$6M; Series A $3.3M–$16M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
  • Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
  • Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Show all investments...

O2h Ventures
VC Fund · 20 investments in Europe Biotechnology startups

Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Hungary

Investor stats

  • Total investments: 39
  • Round size: Seed $655k–$7.9M; Series A $1.9M–$26M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
  • Neurocentrx — Neurocentrx is a specialty pharma company, developing and in-licensing products in pain, palliative care, psychiatry and mood disorders.
  • Alevin Therapeutics — Our mission is to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies
Show all investments...

Auriga Partners
VC Fund · Paris, Ile-de-France, France · 20 investments in Europe Biotechnology startups

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 128
  • Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Amplitude — Amplitude is a leading manufacturer of femtosecond lasers. We are laying the foundations for advances in science, industry, and health care.
  • Pherecydes Pharma — Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
  • Median Technologies — We harness the power of Imaging Phenomics to contribute to the development of next generation treatments and care strategies for patients in need.
Show all investments...

Northstar Ventures
VC Fund · Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom · 19 investments in Europe Biotechnology startups

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Show more...

Investment focus

  • Industry: Software, Health Care, E-Commerce
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Indonesia

Investor stats

  • Total investments: 190
  • Round size: Seed $39k–$1.8M; Series A $851k–$9.7M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
  • NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
  • CellRev — high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
Show all investments...

GM&C Life Sciences Fund
VC Fund · Alderley Edge, Cheshire, United Kingdom · 19 investments in Europe Biotechnology startups

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Italy, Germany

Investor stats

  • Total investments: 33
  • Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
  • Lead/follow: 67% lead, 33% follow

Portfolio highlights

  • Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
  • Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
  • Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Show all investments...

Deepbridge Capital
VC Fund · Chester, Cheshire, United Kingdom · 19 investments in Europe Biotechnology startups

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Australia, Singapore

Investor stats

  • Total investments: 84
  • Round size: Seed $152k–$2.6M; Series A $2M–$15M
  • Lead/follow: 74% lead, 26% follow
  • Last fund: Likely still investing — raised $1.4M in 2022

Portfolio highlights

  • HeadBox — HeadBox connects corporate event planners with 100,000+ unique, inspiring, iconic, and creative spaces worldwide for meetings and events.
  • Touch Biometrix — Welcome at Touch Biometrix. Find out more about The Future of Fingerprint Biometrics!
  • Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
AdBio partners
VC Fund · Paris, Ile-de-France, France · 19 investments in Europe Biotechnology startups

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: France, Spain, Belgium

Investor stats

  • Total investments: 31
  • Round size: Seed $2.2M–$18M; Series A $19M–$37M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — raised $116M in 2021

Portfolio highlights

  • DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
  • AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
  • Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Show all investments...

Idinvest Partners
VC Fund · Paris, Ile-de-France, France · 19 investments in Europe Biotechnology startups

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series B, Series A
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 252
  • Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $88M in 2021

Portfolio highlights

  • Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
  • Glovo — Glovo delivers the best products of your city in less than 1 hour
  • Stanley Robotics — Stanley Robotics is a DeepTech business helping the transportation and logistics industries digitalise and robotise outdoor operations.
Show all investments...

Wren Capital
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotechnology startups

Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 33
  • Round size: Seed $1.1M–$5.2M; Series A $2M–$32M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
  • SenseAI
  • Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
Show all investments...

Ysios Capital
VC Fund · San Sebastian, Pais Vasco, Spain · 18 investments in Europe Biotechnology startups

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Spain, United States, Switzerland

Investor stats

  • Total investments: 79
  • Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
  • Lead/follow: 30% lead, 70% follow

Portfolio highlights

  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
  • Cytoki Pharma — Cytoki Pharma is a biotechnology company developing a portfolio of IL-22-based drugs as a new treatment paradigm for serious diseases involving epithelial injury.
Show all investments...

Chalmers Ventures AB
VC Fund · Göteborg, Vastra Gotaland, Sweden · 18 investments in Europe Biotechnology startups

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Pre-Seed, Seed
  • Geography: Sweden

Investor stats

  • Total investments: 188
  • Round size: Seed $289k–$2.7M; Pre-Seed $5k–$296k
  • Lead/follow: 48% lead, 52% follow

Portfolio highlights

  • Repli5 — Enabling autonomous vehicles with synthetic data. We automate the creation of synthetic data and digital twins.
  • Vesiro — Install our Elasticsearch plugin and keep your current setup. Just faster.
  • Ambidex AB — helps food retailers create new revenue streams on their refrigeration systems by stabilizing the electricity grid.
Show all investments...

Newable Private Investing
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotechnology startups

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 102
  • Lead/follow: no public data

Portfolio highlights

  • Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
  • Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
  • EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
Show all investments...

Octopus Ventures
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotechnology startups

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 369
  • Round size: Seed $1.9M–$13M; Series A $3M–$21M; Series B $7.5M–$48M
  • Lead/follow: 57% lead, 43% follow
  • Last fund: May invest from a new fund soon — raised $101M in 2019

Portfolio highlights

  • Wazoku — Wazoku - Where Innovation Works Wazoku
  • CertiVox — CertiVox solutions deliver simple, powerful information security to all things Internet (mainframes, too!), protecting business and individual privacy through the cloud and at rest. CertiVox was founded in 2009 to provide technology and services based on a simple belief: that everyone deserves the right to secure their information exchangessimply and easily. CertiVox's leading-edge encryption, key management and identity management solutions are currently in use at hundreds of the world’s leading corporations and used by individuals across the globe to protect their privacy.The companies passion is to create and share unique, cutting-edge cryptographic innovations for enterprise cloud computing and all things Internet. CertiVox are the only company in the global market today that has the technology in place to arm businesses and individuals with easy-to-use certificateless security solutions for any device and platform.Whether you are a business that wants to safeguard your company’s intellectual property, an ISV or SaaS provider that needs to embed cryptography and key management into your application, or an individual who wants to preserve the privacy of your personal data, CertiVox gives you the power to secure your information for all things Internet.CertiVox’s leading-edge solutions – including MIRACL (Multiprecision Integer and Rational Arithmetic C/C++ Library) Cryptographic SDK, on-demand encryption Key Management Service (KMS) and Identity Management Service (IDMS) – enable cloud service providers, independent software vendors (ISVs), communication providers, and smart device and semiconductor manufacturers to secure their voice and data communication solutions with ease.The PrivateSky Secure Information Exchange Service (SIX) gives individuals, businesses and their partners and customers easy-to-use tools to quickly encrypt email, files and documents without complex infrastructure or user burden. Compliance with mandatory encryption and privacy statues has never been easier.The bottom line: CertiVox's revolutionary certificateless cryptography, identity and key management solutions have taken the hassle out of Internet security, making it easy to securely exchange your information in any form, any time.
  • Mojo — Join 600,000+ men worldwide using AI-powered coaches to build a performance mindset and take back control of their love lives.
Show all investments...

Cambridge Innovation Capital
VC Fund · Cambridge, Cambridgeshire, United Kingdom · 18 investments in Europe Biotechnology startups

As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United Kingdom, United States, Ireland

Investor stats

  • Total investments: 97
  • Round size: Seed $3.9M–$23M; Series A $2M–$73M; Series B $8.5M–$65M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
  • Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
  • Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
Show all investments...

Hoxton Ventures
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotechnology startups

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Canada

Investor stats

  • Total investments: 129
  • Round size: Seed $1.8M–$12M; Series A $5M–$29M
  • Lead/follow: 43% lead, 57% follow

Portfolio highlights

  • Preply — Looking for a tutor? Preply is the best platform for private online lessons with a flexible payment system and affordable prices. Book your first lesson.
  • Fabrica AI — Fabrica AI offers a revolutionary platform for faster robot development, using custom hardware designs and learned optimal control to increase efficiency while minimizing complexity and cost. With a vision for a future where robot development takes days, not years.
  • Peptone — We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
Show all investments...

PMV
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 17 investments in Europe Biotechnology startups

Do and dare company

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Seed
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 146
  • Round size: Seed $549k–$4.3M; Series A $2.7M–$40M
  • Lead/follow: 23% lead, 77% follow

Portfolio highlights

  • RheaVita — Streamline your lyophilization process with RheaVita's innovative freeze-drying technologies, accelerating drug development while ensuring compliance and efficiency. Discover our solutions today.
  • LindaCare — LindaCare develops solutions for implantable cardiac device remote monitoring. From intuitive dashboards for caregivers to managed remote monitoring service, LindaCare is at the forefront of the monitoring revolution.
  • Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology VC Funds in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 VC funds investing in Europe Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists